Sana Announces Upsized Pricing of Initial Public Offering
04 Februar 2021 - 5:22AM
Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused
on creating and delivering engineered cells as medicines, today
announced the pricing of its upsized initial public offering of
23,500,000 shares of its common stock at a public offering price of
$25.00 per share. All of the shares of common stock are being
offered by Sana. The gross proceeds from the offering, before
deducting underwriting discounts and commissions and other offering
expenses payable by Sana, are expected to be $587.5 million. Sana’s
common stock is expected to begin trading on The Nasdaq Global
Select Market on February 4, 2021, under the ticker symbol “SANA.”
The offering is expected to close on February 8, 2021, subject to
the satisfaction of customary closing conditions. In addition, Sana
has granted the underwriters a 30-day option to purchase up to an
additional 3,525,000 shares of common stock at the initial public
offering price, less the underwriting discounts and commissions,
and, if exercised in full, would result in aggregate gross proceeds
of approximately $675.6 million.
Morgan Stanley, Goldman Sachs & Co. LLC,
J.P. Morgan and BofA Securities are acting as joint book-running
managers for the offering.
Registration statements relating to the shares
being sold in this offering were filed with the Securities and
Exchange Commission and became effective on February 3, 2021. The
offering is being made only by means of a prospectus, copies of
which may be obtained, when available, from: Morgan Stanley,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014, or by email at prospectus@morganstanley.com;
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, by telephone at (866) 471-2526, or
by email at prospectus-ny@ny.email.gs.com; J.P. Morgan Securities
LLC, Attention: Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by email at
prospectus-eq_fi@jpmorgan.com, or by telephone at (866) 803-9204;
or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd
Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department,
or by email at dg.prospectus_requests@bofa.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Sana
Sana Biotechnology, Inc. is focused on creating
and delivering engineered cells as medicines for patients. Sana
shares a vision of repairing and controlling genes, replacing
missing or damaged cells, and making its therapies broadly
available to patients. Sana is more than 250 people working
together to create an enduring company that changes how the world
treats disease. Sana has operations in Seattle, Cambridge, and
South San Francisco.
Investor Relations:Nicole
Keithinvestor.relations@sana.com
Media:Morgan Warners, Finsbury Glover
Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
Von Jul 2023 bis Jul 2024